Context Therapeutics Inc.
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company developing T cell-engaging bispecific antibodies for solid tumors. Its pipeline has three product candidates: CTIM-76, targeting CLDN6, and CT-95, targeting mesothelin, both in Phase 1 trials; and CT-202, targeting Nectin-4, which… From the company’s description.
In fiscal 2025, Context Therapeutics Inc. reported a net loss of $36.12M. Operations used $26.39M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Context Therapeutics Inc. does
In the company’s own words
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company developing T cell-engaging bispecific antibodies for solid tumors. Its pipeline has three product candidates: CTIM-76, targeting CLDN6, and CT-95, targeting mesothelin, both in Phase 1 trials; and CT-202, targeting Nectin-4, which is in preclinical development. The candidates are designed to recruit T cells to attack cancer cells expressing their respective targets. CTIM-76 is being evaluated in patients with selected gynecologic and testicular cancers, while CT-95 is being studied in patients with solid tumors including ovarian, pancreatic and mesothelioma. CT-202 is designed for preferential activity in the acidic tumor environment. The company focuses its research and development on advancing these programs and expanding its oncology pipeline. It acquired CT-95 assets from Link in 2024 and licensed CT-202 from BioAtla that year; its CLDN6 program was developed with Integral Molecular. Context relies on third parties for product manufacturing and clinical trial services, and has no commercial products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1842952
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Context Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Context Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Context Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Context Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Context Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”